- Home
- AFCG vs MGNX Comparison
AFCG vs MGNX Comparison
Compare AFCG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- MGNX
- Stock Information
- Founded
- AFCG 2020
- MGNX 2000
- Country
- AFCG United States
- MGNX United States
- Employees
- AFCG N/A
- MGNX N/A
- Industry
- AFCG Real Estate Investment Trusts
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- AFCG Real Estate
- MGNX Health Care
- Exchange
- AFCG Nasdaq
- MGNX Nasdaq
- Market Cap
- AFCG 92.9M
- MGNX 99.7M
- IPO Year
- AFCG 2021
- MGNX 2013
- Fundamental
- Price
- AFCG $3.80
- MGNX $1.78
- Analyst Decision
- AFCG Hold
- MGNX Hold
- Analyst Count
- AFCG 5
- MGNX 6
- Target Price
- AFCG $8.17
- MGNX $3.20
- AVG Volume (30 Days)
- AFCG 270.1K
- MGNX 614.2K
- Earning Date
- AFCG 11-12-2025
- MGNX 11-04-2025
- Dividend Yield
- AFCG 15.87%
- MGNX N/A
- EPS Growth
- AFCG N/A
- MGNX N/A
- EPS
- AFCG N/A
- MGNX N/A
- Revenue
- AFCG $8,721,514.00
- MGNX $165,495,000.00
- Revenue This Year
- AFCG N/A
- MGNX N/A
- Revenue Next Year
- AFCG $13.92
- MGNX N/A
- P/E Ratio
- AFCG N/A
- MGNX N/A
- Revenue Growth
- AFCG N/A
- MGNX 303.47
- 52 Week Low
- AFCG $3.44
- MGNX $0.99
- 52 Week High
- AFCG $10.50
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- AFCG 34.71
- MGNX 51.87
- Support Level
- AFCG $3.69
- MGNX $1.69
- Resistance Level
- AFCG $4.01
- MGNX $1.83
- Average True Range (ATR)
- AFCG 0.16
- MGNX 0.10
- MACD
- AFCG -0.05
- MGNX 0.00
- Stochastic Oscillator
- AFCG 5.36
- MGNX 56.00
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.